Log in

NASDAQ:GLYC - GlycoMimetics Stock Price, Forecast & News

$5.96
-0.20 (-3.25 %)
(As of 12/15/2019 04:00 PM ET)
Today's Range
$5.89
Now: $5.96
$6.29
50-Day Range
$4.89
MA: $5.74
$6.59
52-Week Range
$2.64
Now: $5.96
$13.56
Volume135,629 shs
Average Volume280,014 shs
Market Capitalization$258.43 million
P/E RatioN/A
Dividend YieldN/A
Beta2.68
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Price / Sales12,921.28
Book Value$4.76 per share

Profitability

Net Income$-48,270,000.00

Miscellaneous

Employees50
Market Cap$258.43 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.


GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How were GlycoMimetics' earnings last quarter?

GlycoMimetics Inc (NASDAQ:GLYC) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.39) by $0.08. View GlycoMimetics' Earnings History.

When is GlycoMimetics' next earnings date?

GlycoMimetics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for GlycoMimetics.

What price target have analysts set for GLYC?

6 equities research analysts have issued 12-month price targets for GlycoMimetics' shares. Their forecasts range from $5.00 to $18.00. On average, they anticipate GlycoMimetics' share price to reach $9.25 in the next year. This suggests a possible upside of 55.2% from the stock's current price. View Analyst Price Targets for GlycoMimetics.

What is the consensus analysts' recommendation for GlycoMimetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.

What are Wall Street analysts saying about GlycoMimetics stock?

Here are some recent quotes from research analysts about GlycoMimetics stock:
  • 1. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (10/9/2019)
  • 2. HC Wainwright analysts commented, "We base our $23 price target on probability-adjusted forecasts for uproleselan in AML as well as rivipansel in SCD VOC. We use the net present value of our revenue forecast through 2027, apply a 60% POS for AML and a 70% POS for SCD 4x price/sales multiple for AML, and estimated 2019 year-end net cash of $3.11 per share, to arrive at our price target. Our P/S multiple of 4x is inline with GlycoMimetics’ peers that range between 2-5x." (4/12/2019)

Has GlycoMimetics been receiving favorable news coverage?

News coverage about GLYC stock has been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GlycoMimetics earned a news sentiment score of -1.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for GlycoMimetics.

Who are some of GlycoMimetics' key competitors?

What other stocks do shareholders of GlycoMimetics own?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the folowing people:
  • Ms. Rachel K. King, Pres, CEO & Director (Age 60)
  • Mr. Brian M. Hahn, Sr. VP, CFO & Sec. (Age 45)
  • Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 66)
  • Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 51)
  • Mr. Henry Flanner, VP of Technical Operations

Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Redmile Group LLC (4.61%), State Street Corp (1.54%), Millennium Management LLC (0.53%), Alps Advisors Inc. (0.20%), Squarepoint Ops LLC (0.11%) and Barclays PLC (0.09%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius, John L Magnani and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.

Which major investors are selling GlycoMimetics stock?

GLYC stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Redmile Group LLC and Alps Advisors Inc.. View Insider Buying and Selling for GlycoMimetics.

Which major investors are buying GlycoMimetics stock?

GLYC stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Prentiss Smith & Co. Inc., Tower Research Capital LLC TRC, California Public Employees Retirement System and Barclays PLC. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il and Daniel M Junius. View Insider Buying and Selling for GlycoMimetics.

How do I buy shares of GlycoMimetics?

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $5.96.

How big of a company is GlycoMimetics?

GlycoMimetics has a market capitalization of $258.43 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-48,270,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.View Additional Information About GlycoMimetics.

What is GlycoMimetics' official website?

The official website for GlycoMimetics is http://www.glycomimetics.com/.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]


MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  517
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Featured Article: What is net income?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel